{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:53:56Z","timestamp":1792155236390,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA71921-01"],"award-info":[{"award-number":["1R01CA71921-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1UO1CA77150-01"],"award-info":[{"award-number":["1UO1CA77150-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5 R01 CA098897 04"],"award-info":[{"award-number":["5 R01 CA098897 04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["N01-CN-85186"],"award-info":[{"award-number":["N01-CN-85186"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5 R01 CA074880 08"],"award-info":[{"award-number":["5 R01 CA074880 08"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA38926"],"award-info":[{"award-number":["CA38926"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA32102"],"award-info":[{"award-number":["CA32102"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2PC50CA091846-06S2"],"award-info":[{"award-number":["2PC50CA091846-06S2"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["SWOG0353"],"award-info":[{"award-number":["SWOG0353"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.urolonc.2007.11.033","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T19:10:56Z","timestamp":1204830656000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Seth P.","family":"Lerner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Sucharew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2007.11.033_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Effect of bacillus Calmette-Guerin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2007.11.033_bib2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: 10-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2007.11.033_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)36724-1","article-title":"Management of Stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2007.11.033_bib4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1A, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"Supp","key":"10.1016\/j.urolonc.2007.11.033_bib5","article-title":"A Phase IIB trial of BCG combined with interferon alpha for bladder cancer","volume":"163","author":"Esuvaranathan","year":"2000","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2007.11.033_bib6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter Phase II trial of combination bacillus Calmette-Guerin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2007.11.033_bib7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2007.11.033_bib8","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/0959-8049(95)00287-S","article-title":"Factors affecting recurrence and progression in superficial bladder tumors","volume":"31A","author":"Kurth","year":"1995","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2007.11.033_bib9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0022-5347(01)62517-5","article-title":"Relationship among cystectomy, microvessel density, and prognosis in Stage T1 transitional cell carcinoma of the bladder","volume":"160","author":"Dinney","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.11.033_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(18)31712-9","article-title":"Outcomes of patients with clinical T1 Grade 3 bladder urothelial carcinoma treated with radical cystectomy","volume":"177","author":"Gupta","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.11.033_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2307\/2532300","article-title":"Relative risk regression trees for censored survival data","volume":"48","author":"LeBlanc","year":"1992","journal-title":"Biometrics"},{"issue":"3 Pt 1","key":"10.1016\/j.urolonc.2007.11.033_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2007.11.033_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2007.11.033_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(05)65969-1","article-title":"Clinical under staging of high risk non-muscle invasive urothelial carcinoma treated with radical cystectomy","volume":"166","author":"Dutta","year":"2001","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2007.11.033_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"issue":"Suppl 3","key":"10.1016\/j.urolonc.2007.11.033_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000052392","article-title":"Keyhole limpet hemocyanin for carcinoma in situ of the bladder: A long-term follow-up study","volume":"37","author":"Jurincic-Winkler","year":"2000","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2007.11.033_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-\u03b12b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2007.11.033_bib18","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2007.11.033_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2007.11.033_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: Significance of concomitant carcinoma in situ","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143907003225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143907003225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:21:35Z","timestamp":1778588495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143907003225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1078143907003225"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.11.033","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}